What Is GLP-1? Glucagon-Like Peptide-1 Explained

Key Takeaways

• Hormone class: Incretin; member of the glucagon peptide family. Encoded by the proglucagon gene (GCG) and processed tissue-specifically in intestinal L-cells.
• Primary function: Stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite.
• Where it comes from: Produced and secreted by intestinal L-cells of the small intestine and colon; also by neurons in the brainstem (nucleus tractus solitarius).
• Secretion trigger: Food intake — particularly dietary fats, proteins, and fermentable carbohydrates. Levels rise within roughly 10–15 minutes of eating.
• Half-life: Approximately 2 minutes in circulation; rapidly degraded by dipeptidyl peptidase-4 (DPP-4).
• Measurable range: Fasting: approximately 1–5 pmol/L; postprandial peak: 10–50 pmol/L depending on meal composition and individual variation. Reference ranges vary by laboratory and assay method — your provider will interpret your specific results in context.
• Key drugs targeting this pathway: GLP-1 receptor agonists (semaglutide/Ozempic, Wegovy, Rybelsus; liraglutide/Victoza, Saxenda; tirzepatide/Mounjaro, Zepbound as dual GLP-1/GIP agonist; exenatide/Byetta twice-daily, Bydureon weekly; dulaglutide/Trulicity); DPP-4 inhibitors (sitagliptin, saxagliptin) which extend the hormone's half-life.
• FDA approval status: As of April 2026, semaglutide is FDA-approved for type 2 diabetes (Ozempic injectable; Rybelsus oral) and chronic weight management (Wegovy); liraglutide for type 2 diabetes (Victoza) and obesity (Saxenda); tirzepatide for type 2 diabetes (Mounjaro), and for chronic weight management and moderate-to-severe obstructive sleep apnea in adults with obesity (Zepbound). In March 2024, FDA added a cardiovascular risk reduction indication to Wegovy for adults with established cardiovascular disease and obesity or overweight.

What GLP-1 Is and Where It Comes From

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid incretin hormone produced by intestinal L-cells in response to food intake. It is derived from the proglucagon protein via tissue-specific processing and acts on GLP-1 receptors throughout the pancreas, brain, gut, heart, and kidneys to regulate insulin secretion, glucagon suppression, gastric emptying, and appetite.

The proglucagon gene (GCG) encodes a 160-amino acid precursor protein — proglucagon — from which multiple active peptides are cleaved through the action of prohormone convertases. The tissue specificity of this processing is what distinguishes intestinal L-cells from pancreatic alpha cells: in the pancreas, prohormone convertase 2 cleaves proglucagon to yield glucagon; in the intestinal L-cell, prohormone convertase 1/3 yields GLP-1 and GLP-2 instead. Sandoval and D'Alessio, in a comprehensive 2015 review in Physiological Reviews, detailed how tissue-specific proglucagon processing generates the full incretin peptide family from a single gene product — a model of biological economy that underscores the evolutionary integration of gut and pancreatic hormone signaling.

L-cells are most densely distributed in the distal small intestine and colon but are present throughout the gut. GLP-1 is also produced by neurons in the nucleus tractus solitarius of the brainstem, where it contributes to central appetite regulation through direct central nervous system signaling pathways independent of the peripheral gut-hormone route.

How GLP-1 Works in the Body

GLP-1 acts on receptors distributed across multiple organ systems. This anatomical breadth explains both its physiological importance and the range of clinical effects observed when its receptor is activated pharmacologically.

Pancreatic effects: insulin and glucagon

GLP-1's defining pharmacological property is glucose-dependent insulin secretion: it stimulates beta cells of the pancreas to release insulin only when blood glucose is elevated, not at normal fasting levels. This glucose-dependency is the key reason why GLP-1 receptor agonists carry a low inherent risk of hypoglycemia compared to other insulin-secretagogues. Simultaneously, GLP-1 suppresses glucagon from pancreatic alpha cells, reducing hepatic glucose output. Together, these two effects produce the central glycemic benefit that defined GLP-1's clinical value. Holst's 2007 review in Physiological Reviews established the molecular basis for glucose-dependent GLP-1 receptor signaling in beta and alpha cells, describing how the cAMP/PKA pathway mediates the insulin-stimulatory effect and its glucose-dependency.

Gastric emptying and satiety signals

GLP-1 slows gastric emptying — reducing the rate at which ingested food exits the stomach — which blunts the postprandial glucose spike by slowing nutrient delivery to the small intestine. Independently, GLP-1 acts on the hypothalamus and brainstem via the vagus nerve to signal satiety and reduce food intake. Hellström, in a 2009 review in Regulatory Peptides, reviewed GLP-1's gastrointestinal motility effects in detail. Van Bloemendaal and colleagues, in a 2014 human fMRI study published in Diabetes, showed using functional neuroimaging that GLP-1 receptor activation reduces activity in reward and appetite brain regions in living human subjects — providing direct central nervous system evidence for GLP-1's appetite-suppressing effects beyond the peripheral gut-to-vagus pathway. Hong and Kim, in a 2024 review in Current Opinion in Endocrinology, Diabetes and Obesity, placed GLP-1 within the integrated gut hormone appetite regulation system alongside PYY, CCK, and ghrelin.

Half-life and DPP-4 degradation

Endogenous GLP-1 has a circulating half-life of approximately 2 minutes. It is rapidly cleaved and inactivated by dipeptidyl peptidase-4 (DPP-4), a serine protease expressed on the surface of capillary endothelial cells that removes the first two amino acids from the active form, creating an inactive metabolite. This short half-life is the central pharmacological challenge that makes endogenous GLP-1 impossible to use therapeutically without modification — and precisely what pharmaceutical analog development solved. Holst's 2007 review established DPP-4 degradation as the primary determinant of GLP-1's brief circulating window. This same mechanism is exploited by DPP-4 inhibitors (sitagliptin, saxagliptin), which extend endogenous GLP-1 activity by blocking the degrading enzyme.

Effects beyond glycemia: cardiovascular, renal, and neurological

GLP-1 receptors are expressed in the heart, kidneys, and brain, and research has established effects that extend well beyond glucose control. Drucker, in a 2016 review in Cell Metabolism, reviewed GLP-1's direct and indirect cardiovascular mechanisms, identifying cardioprotective effects including reduced ischemia-reperfusion injury, improved endothelial function, and anti-inflammatory actions in cardiac tissue. The clinical scale of these effects was established by Kristensen and colleagues, in a 2019 meta-analysis published in The Lancet Diabetes and Endocrinology that pooled data from 7 cardiovascular outcome trials covering 56,004 participants: GLP-1 receptor agonists were associated with reductions of approximately 12%, 12%, 16%, and 17% respectively in major adverse cardiovascular events, all-cause mortality, stroke, and a composite kidney outcome, though effect sizes varied significantly across individual trials and compounds in the class. In March 2024, FDA approved Wegovy (semaglutide 2.4 mg) for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight — at the time of approval, the first on-label cardiovascular-outcomes indication in the GLP-1 RA class. In January 2025, based on the FLOW trial, FDA approved a renal-outcomes indication for Ozempic in adults with type 2 diabetes and chronic kidney disease — the first on-label renal indication for any GLP-1 receptor agonist. Li and colleagues, in a 2021 review in Frontiers in Endocrinology, reviewed GLP-1 biology beyond diabetes, covering Alzheimer's disease, hypertension, and non-CV-MACE indications as areas of active investigation. As of April 2026, use in these investigational indications is not supported by FDA approval and remains investigational.

What Regulates GLP-1 Secretion

What triggers GLP-1 release

The primary stimulus for GLP-1 secretion is food intake. Levels rise within 10–15 minutes of eating and remain elevated for several hours, returning to fasting levels as gastric emptying completes. The macronutrient profile of the meal affects the magnitude of GLP-1 release: dietary fat, protein, and fermentable carbohydrates are all effective stimuli, while highly refined carbohydrates with low fiber content produce smaller responses. Bile acids released during fat digestion activate intestinal L-cells via the TGR5 receptor on their basolateral surface. Short-chain fatty acids produced during gut microbiome fermentation of dietary fiber stimulate L-cells via FFA2 and FFA3 receptors. Kuhre, Holst, and Kappe, in their 2016 Clinical Science review, described the full regulatory biology of L-cell secretion, including the neuroendocrine, nutritional, and microbial inputs that determine postprandial GLP-1 output.

What suppresses GLP-1 secretion

Obesity, insulin resistance, and type 2 diabetes are all associated with a blunted incretin response — reduced postprandial GLP-1 secretion relative to lean, insulin-sensitive individuals. Nauck and Meier, in a 2018 review in Diabetes, Obesity and Metabolism, documented the impaired incretin response in type 2 diabetes and proposed that this impairment — whether cause or consequence of the metabolic state — contributes to the rationale for pharmacological GLP-1 supplementation. Fasting states reduce GLP-1 to its basal level; certain medications including some immunosuppressants and corticosteroids are also associated with reduced GLP-1 activity.

When GLP-1 Levels Are Low or High

Conditions associated with impaired GLP-1 secretion

Reduced GLP-1 secretion is associated with type 2 diabetes, obesity, and insulin resistance. The mechanism is not fully characterized but likely involves altered L-cell function, changes in gut microbiome composition affecting short-chain fatty acid production, and neural signaling dysregulation. Bariatric surgery — particularly Roux-en-Y gastric bypass — produces a dramatic and sustained increase in postprandial GLP-1 levels, a finding that contributed to the hypothesis that elevated GLP-1 mediates a portion of the metabolic benefits of these procedures independent of caloric restriction. Nauck and Meier documented this effect in their 2018 review alongside the impaired incretin response data, establishing a physiological bookend: the conditions that suppress GLP-1 (obesity, insulin resistance) are also those most improved by interventions that elevate it (surgery, pharmacological agonism). Yabe and Seino, in a 2011 review in Progress in Biophysics and Molecular Biology, compared GLP-1 and GIP effects on insulin secretion and beta-cell preservation, providing mechanistic context for why GLP-1's glucose-dependent action makes it pharmacologically preferable to earlier incretin strategies.

Pharmacological elevation: what GLP-1 receptor agonists achieve

GLP-1 receptor agonists produce circulating GLP-1-equivalent activity at concentrations substantially above physiological postprandial peaks. This supraphysiological receptor activation is responsible for both the therapeutic effects — pronounced appetite suppression, sustained insulin stimulation, and the cardiovascular effects described above — and the side effect profile (nausea, vomiting, gastric slowing, and dose-dependent gastrointestinal effects) that characterize this drug class. Understanding the distinction between physiological GLP-1 secretion and pharmacological receptor activation matters: natural strategies that modestly support endogenous GLP-1 secretion operate through a fundamentally different mechanism and cannot be expected to produce effects equivalent to pharmaceutical-grade receptor agonism. Drucker and Nauck, in a 2006 Lancet review, introduced the incretin therapy framework and established this distinction as foundational to understanding the drug class.

Testing GLP-1 Levels: What to Know

GLP-1 can be measured directly in blood, but direct GLP-1 testing is not standard clinical practice. What is clinically meaningful is understanding the downstream biomarkers that reflect GLP-1 pathway activity in the metabolic system it regulates.

Direct GLP-1 measurement

Fasting plasma GLP-1 is typically in the range of 1–5 pmol/L; postprandial peaks reach 10–50 pmol/L depending on meal composition, with some research citing higher peaks after high-fat meals. Reliable measurement requires specialized assay conditions including immediate sample processing with DPP-4 inhibitors to prevent in-vitro degradation — which is why direct GLP-1 testing is uncommon in routine clinical practice. Reference ranges vary by laboratory and assay methodology. All results should be interpreted in context by a qualified provider.

Downstream biomarkers that reflect GLP-1 pathway activity

• Fasting glucose
  • What it reflects: Blood sugar in the fasted state
  • Relevance to GLP-1 pathway: GLP-1 stimulates glucose-dependent insulin release; elevated fasting glucose may indicate impaired incretin response. Fasting glucose is a primary endpoint in metabolic assessment.
• HbA1c
  • What it reflects: 90-day average blood glucose
  • Relevance to GLP-1 pathway: Primary endpoint in all major GLP-1 RA clinical trials (SUSTAIN, PIONEER, STEP, SCALE programs); reflects long-term glucose control downstream of insulin/glucagon balance. Understanding your HbA1c before starting any GLP-1 therapy provides the reference against which change becomes interpretable.
• Fasting insulin
  • What it reflects: Basal insulin secretion and beta-cell function
  • Relevance to GLP-1 pathway: GLP-1 augments glucose-stimulated (not fasting) insulin release. Elevated fasting insulin may indicate insulin resistance rather than GLP-1 pathway dysfunction specifically, but provides critical metabolic context.
• Triglycerides
  • What it reflects: Hepatic lipid metabolism and cardiovascular metabolic risk
  • Relevance to GLP-1 pathway: GLP-1 RA trials consistently show improvements in triglycerides alongside weight and glucose outcomes. Baseline triglycerides establish the pre-treatment lipid reference point.
• hs-CRP
  • What it reflects: Systemic inflammation
  • Relevance to GLP-1 pathway: GLP-1 RAs are associated with reductions in hs-CRP in clinical trials; baseline hs-CRP provides the inflammatory reference point for tracking anti-inflammatory response to any metabolic intervention.
• ALT (alanine aminotransferase)
  • What it reflects: Liver enzyme activity; hepatocellular health
  • Relevance to GLP-1 pathway: GLP-1 RAs are being studied for NASH; liver enzymes are standard pre-treatment baseline assessment in metabolically overweight individuals. Elevated ALT may indicate hepatic fat accumulation in the population most likely to be considering GLP-1 therapy.
• eGFR (estimated glomerular filtration rate)
  • What it reflects: Kidney filtration function
  • Relevance to GLP-1 pathway: GLP-1 receptors are expressed in the kidneys; GLP-1 receptor agonists have documented renal-outcome effects. The Kristensen meta-analysis (2019) reported a 17% reduction in composite kidney outcomes in pooled cardiovascular-outcome-trial data, and the FLOW trial (2024) supported the January 2025 FDA approval of an Ozempic renal-outcomes indication in adults with type 2 diabetes and chronic kidney disease. Baseline eGFR is part of standard pre-treatment renal assessment.

Reference ranges vary by laboratory and individual. Your provider will interpret your specific results in the context of your full clinical picture.

Understanding your blood sugar and insulin sensitivity markers before starting any GLP-1 medication or making lifestyle changes provides the metabolic reference against which any subsequent change becomes interpretable — that is the principle underlying the testing-first approach Superpower takes to preventive health.

FDA-Approved Medications That Target This Pathway

GLP-1 receptor agonists are not simply "more GLP-1." They are engineered peptides or small molecules designed to activate the GLP-1 receptor with greater potency and duration than the endogenous hormone, which is degraded within minutes of secretion. The key engineering advances are DPP-4 resistance (achieved through structural modifications to the peptide backbone) and albumin or fatty acid binding (which extends half-life through reduced renal clearance). Nauck and Meier, in a 2021 state-of-the-art review in Molecular Metabolism, framed the clinical framework for distinguishing the hormone from its therapeutic analogs.

GLP-1 receptor agonists

As of April 2026, the FDA-approved GLP-1 receptor agonists include: semaglutide (Ozempic for type 2 diabetes, 2017; with a January 2025 added indication to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial; Wegovy for chronic weight management, 2021, with a March 2024 indication added for reduction of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight; Rybelsus as an oral tablet for type 2 diabetes only, 2019; with a higher-dose oral semaglutide formulation approved in April 2025 for chronic weight management, extending oral GLP-1 access beyond type 2 diabetes); liraglutide (Victoza for type 2 diabetes, 2010; Saxenda for obesity, 2014); exenatide (Byetta twice-daily, 2005; Bydureon weekly, 2012); and dulaglutide (Trulicity, 2014). Tirzepatide (Mounjaro for type 2 diabetes, 2022; Zepbound for chronic weight management, 2023, with an additional indication for moderate-to-severe obstructive sleep apnea in adults with obesity added to Zepbound in December 2024) is a dual GLP-1/GIP receptor agonist — it activates both the GLP-1 receptor and the gastric inhibitory polypeptide (GIP) receptor. These are prescription medications. Eligibility, dosing, and monitoring are determined by a licensed provider. For condition-specific context, see Superpower's semaglutide overview and tirzepatide overview. Note: both compounds are FDA-approved prescription drugs. Following the resolution of the 2022–2024 semaglutide and tirzepatide shortages, routine 503A compounding of these molecules is no longer supported by FDA shortage-based enforcement discretion; any compounded formulation now requires a patient-specific prescription with a documented clinically significant difference from the FDA-approved product.

DPP-4 inhibitors

A distinct drug class that works by inhibiting DPP-4, the enzyme that degrades endogenous GLP-1, thereby extending its circulating half-life rather than activating the receptor directly. Examples include sitagliptin (Januvia, approved 2006), saxagliptin (Onglyza, approved 2009), and alogliptin (Nesina, approved 2013). Note: saxagliptin and alogliptin carry FDA labeling regarding heart failure risk based on the SAVOR-TIMI 53 and EXAMINE cardiovascular-outcomes trials. Prescribing decisions are individualized by the evaluating clinician. DPP-4 inhibitors produce more modest glycemic effects than GLP-1 receptor agonists — consistent with the more modest elevation of GLP-1 activity they generate by extending the endogenous hormone's half-life rather than flooding the receptor with an engineered agonist. Gilbert and Pratley, in a 2020 review in Frontiers in Endocrinology, compared GLP-1 analogs and DPP-4 inhibitors, establishing the mechanistic and clinical distinctions between the two pharmacological approaches to the same hormonal pathway.

What to assess before starting GLP-1 therapy

Before starting any GLP-1 receptor agonist, providers typically establish a metabolic baseline. The markers listed above — HbA1c, fasting glucose, fasting insulin, triglycerides, ALT, and eGFR — are standard pre-treatment assessments. A thyroid panel may also be evaluated given the MEN2 contraindication for GLP-1 RAs. Understanding your baseline provides the data against which any medication's effects can be objectively measured.

Dietary and Lifestyle Factors That May Support GLP-1 Secretion

This section covers natural GLP-1 secretion support. The strategies below operate through L-cell stimulation, producing modest effects on endogenous hormone levels. They are not pharmacological GLP-1 receptor activation and cannot replicate the magnitude of effect achieved by prescription GLP-1 receptor agonists. Do not interpret this section as positioning natural strategies as alternatives to prescription therapy.

Dietary fiber and fermentable carbohydrates

Soluble and fermentable dietary fiber has the most consistent and well-replicated human evidence for supporting GLP-1 secretion. Fermentation of fiber by gut microbiota produces short-chain fatty acids — primarily propionate and butyrate — which activate L-cells via FFA2 and FFA3 receptors on the basolateral surface. Multiple short-term human trials have documented higher postprandial GLP-1 levels following high-fiber meals and inulin supplementation compared to low-fiber controls. Evidence grade: multiple human RCTs with consistent direction of effect; mechanistic data corroborating. The effect size at physiological doses is substantially smaller than pharmacological GLP-1 receptor activation.

Dietary protein

Protein-rich meals are associated with higher postprandial GLP-1 secretion than isocaloric carbohydrate-predominant meals in multiple human studies. The proposed mechanism involves direct stimulation of L-cells by amino acids — particularly leucine, glutamine, and phenylalanine. Evidence grade: human observational and short-term intervention data with consistent direction; not powered for clinical metabolic outcomes. These findings support including protein in meals as a reasonable strategy for supporting incretin secretion, without implying clinical equivalence to pharmacological approaches.

Exercise

Both aerobic and resistance exercise have been associated with modestly elevated postprandial GLP-1 levels in human studies. The magnitude is variable across studies and influenced by exercise intensity, fasting status, and individual baseline. The mechanism is incompletely characterized; GLP-1 elevation may be mediated through neural or autonomic pathways triggered by exercise-related signals to the gut. Evidence grade: human observational and exercise intervention data; effect is modest and variable. Exercise's metabolic benefits operate through multiple overlapping pathways beyond GLP-1.

Berberine and other supplements marketed as GLP-1 support

Berberine is increasingly marketed as a "natural GLP-1." The evidence does not support this framing at the clinical outcomes level. Preclinical and small human studies suggest berberine may modulate gut hormone secretion through intestinal mechanisms, and there is evidence of AMPK activation — a pathway shared with metformin. However, as of April 2026, no large completed RCTs demonstrate that berberine produces GLP-1-mediated outcomes (meaningful weight loss, sustained glycemic control) comparable to pharmacological GLP-1 receptor agonists. Claims of equivalence to GLP-1 drugs are not supported by the available evidence. Evidence grade for GLP-1-specific claims: mechanistic and small human studies; no completed large RCTs for GLP-1-specific outcomes.

Side Effects of GLP-1 Receptor Agonists

The side effects widely discussed in media as "GLP-1 side effects" are specifically the side effects of pharmacological GLP-1 receptor agonists — not the endogenous hormone. This distinction matters for readers who want to understand their body's natural signaling separately from the drug effects.

Common side effects (GLP-1 RA drug class, dose-dependent):

• Nausea (most common; typically peaks at dose escalation and diminishes over weeks)
• Vomiting (particularly with higher-dose regimens)
• Diarrhea or constipation (constipation more common with semaglutide)
• Decreased appetite (intended pharmacological effect; also reported as adverse when severe)
• Injection-site reactions (subcutaneous formulations)

Less common but reported:

• Gastroparesis or delayed gastric emptying (may be dose-limiting in susceptible individuals)
• Pancreatitis (rare; contraindicated in individuals with personal or family history of MEN2 or medullary thyroid carcinoma)
• Gallbladder disease (cholelithiasis observed in several GLP-1 RA programs)
• Mood changes (as of April 2026, postmarketing surveillance includes ongoing review of reports of depression and suicidal ideation; causality has not been established)

He and colleagues, in a 2022 systematic review and meta-analysis of 76 randomized clinical trials published in JAMA Internal Medicine, characterized the association of GLP-1 receptor agonist use with gallbladder and biliary disease risk, and gastrointestinal effects remain the most commonly reported side-effect category across the drug class. The side effect profile is drug-specific and dose-dependent. Providers titrate doses to manage gastrointestinal effects. A qualified provider will evaluate individual risk factors before prescribing any GLP-1 receptor agonist.

When These Numbers Matter: Testing Before Acting

The biology of GLP-1 is relevant whether or not someone is considering a GLP-1 medication. Fasting glucose, HbA1c, and insulin levels tell a story about how your metabolic signaling is functioning — specifically the incretin pathway that GLP-1 anchors. If those markers are outside their reference ranges, that information is clinically meaningful on its own terms, before any treatment question is asked. Establishing a metabolic baseline through these markers provides the data that makes any subsequent decision — to pursue lifestyle changes, to inform a conversation with a qualified clinician about your metabolic health, or simply to track trends over time — interpretable. The metabolic health biomarker testing guide covers these markers in detail and explains how they fit together as an integrated picture of metabolic signaling.

That commitment to data before decisions is at the core of what Superpower does — the understanding that knowing your biology is the starting point for every health decision, not an afterthought to it. In a space where the pharmacology of GLP-1 moves as fast as the headlines about it, the enduring value is in understanding the underlying biology clearly enough to evaluate any new development on its merits.

IMPORTANT SAFETY INFORMATION

GLP-1 receptor agonists are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They should not be used during pregnancy or breastfeeding. Pancreatitis has been reported; use with caution in individuals with a history of pancreatitis.

Common side effects include nausea, vomiting, diarrhea, constipation, and injection-site reactions. Serious adverse events are uncommon but include pancreatitis, gallbladder disease, and gastrointestinal obstruction.

As of April 2026, postmarketing surveillance includes ongoing review of reports of depression and suicidal ideation associated with GLP-1 receptor agonists. Causality has not been established.

GLP-1 receptor agonists are prescription-only medications. This article does not constitute medical advice or prescribing guidance. Consult a qualified healthcare provider for evaluation and prescribing decisions. Full prescribing information at dailymed.nlm.nih.gov.